Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.

Revenue
+10.2%
EPS
+450.0%
Free cash flow
+35.6%
Total debt
−6.91%

Quarter to June 2026, against a year earlier

23.74 1.57 −6.20%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
161×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a

Elanco Animal Health Incorporated 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 9:06 AM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed May 6, 2026: no material changes, the filing says